» Articles » PMID: 15616203

Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years After Bariatric Surgery

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2004 Dec 24
PMID 15616203
Citations 1539
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Weight loss is associated with short-term amelioration and prevention of metabolic and cardiovascular risk, but whether these benefits persist over time is unknown.

Methods: The prospective, controlled Swedish Obese Subjects Study involved obese subjects who underwent gastric surgery and contemporaneously matched, conventionally treated obese control subjects. We now report follow-up data for subjects (mean age, 48 years; mean body-mass index, 41) who had been enrolled for at least 2 years (4047 subjects) or 10 years (1703 subjects) before the analysis (January 1, 2004). The follow-up rate for laboratory examinations was 86.6 percent at 2 years and 74.5 percent at 10 years.

Results: After two years, the weight had increased by 0.1 percent in the control group and had decreased by 23.4 percent in the surgery group (P<0.001). After 10 years, the weight had increased by 1.6 percent and decreased by 16.1 percent, respectively (P<0.001). Energy intake was lower and the proportion of physically active subjects higher in the surgery group than in the control group throughout the observation period. Two- and 10-year rates of recovery from diabetes, hypertriglyceridemia, low levels of high-density lipoprotein cholesterol, hypertension, and hyperuricemia were more favorable in the surgery group than in the control group, whereas recovery from hypercholesterolemia did not differ between the groups. The surgery group had lower 2- and 10-year incidence rates of diabetes, hypertriglyceridemia, and hyperuricemia than the control group; differences between the groups in the incidence of hypercholesterolemia and hypertension were undetectable.

Conclusions: As compared with conventional therapy, bariatric surgery appears to be a viable option for the treatment of severe obesity, resulting in long-term weight loss, improved lifestyle, and, except for hypercholesterolemia, amelioration in risk factors that were elevated at baseline.

Citing Articles

Effectiveness of Adjuvant Semaglutide Following Bariatric Metabolic Surgery.

Ferguson J, Fisher O, Talbot M, Rigas G Obes Surg. 2025; 35(3):694-700.

PMID: 39982604 PMC: 11906545. DOI: 10.1007/s11695-025-07703-0.


Management of cardiovascular disease by cerium oxide nanoparticles via alleviating oxidative stress and adipokine abnormalities.

Bashandy S, Elbaset M, Ibrahim F, Abdelrahman S, Moussa S, El-Seidy A Sci Rep. 2025; 15(1):5709.

PMID: 39962072 PMC: 11833101. DOI: 10.1038/s41598-025-85794-6.


Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.

Nie Y, Zhang Y, Liu B, Meng H Obes Surg. 2025; 35(3):808-822.

PMID: 39948306 DOI: 10.1007/s11695-025-07733-8.


A 13-year nationwide analysis of outcomes of non-variceal upper gastrointestinal bleeding in post-bariatric surgery patients.

Pellegrini Jr J, Sodoma A, Greenberg S, Rathi S, Knott N, Pellegrini R Transl Gastroenterol Hepatol. 2025; 10:6.

PMID: 39944580 PMC: 11811552. DOI: 10.21037/tgh-24-100.


Preoperative Nutrition in Bariatric Surgery: A Narrative Review on Enhancing Surgical Success and Patient Outcomes.

Simancas-Racines D, Frias-Toral E, Campuzano-Donoso M, Ramos-Sarmiento D, Zambrano-Villacres R, Reytor-Gonzalez C Nutrients. 2025; 17(3).

PMID: 39940424 PMC: 11820445. DOI: 10.3390/nu17030566.